Atlas Trials

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

Clinical trial NCT06530719 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06530719
Sponsor
Jin Ying
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lung NeoplasmsLung Cancer, Nonsmall Cell
Start date
2024-07-01
Primary completion
2026-05-01
Enrollment
54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.